Analyst Expect Big Moves From Opko Health Inc (NASDAQ: OPK)

Currently, there are 773.28M common shares owned by the public and among those 327.73M shares have been available to trade.

The company’s stock has a 5-day price change of 29.03% and -24.05% over the past three months. OPK shares are trading -20.53% year to date (YTD), with the 12-month market performance down to -13.67% lower. It has a 12-month low price of $0.85 and touched a high of $2.24 over the same period. OPK has an average intraday trading volume of 14.65 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 26.61%, 22.29%, and -16.94% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Opko Health Inc (NASDAQ: OPK) shares accounts for 27.24% of the company’s 773.28M shares outstanding.

It has a market capitalization of $836.39M and a beta (3y monthly) value of 1.80. The earnings-per-share (ttm) stands at -$0.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.42% over the week and 5.81% over the month.

Analysts forecast that Opko Health Inc (OPK) will achieve an EPS of -$0.09 for the current quarter, -$0.09 for the next quarter and -$0.25 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.14 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.02 a year ago. Earnings per share for the fiscal year are expected to decrease by -45.33%, and 30.09% over the next financial year. EPS should grow at an annualized rate of 12.00% over the next five years, compared to 1.56% over the past 5-year period.

Looking at the support for the OPK, a number of firms have released research notes about the stock. Barrington Research stated their Outperform rating for the stock in a research note on June 29, 2023, with the firm’s price target at $2. H.C. Wainwright coverage for the Opko Health Inc (OPK) stock in a research note released on December 15, 2022 offered a Buy rating with a price target of $3. Barrington Research was of a view on January 24, 2022 that the stock is Mkt Perform, while Ladenburg Thalmann gave the stock Buy rating on June 21, 2021, issuing a price target of $7. Piper Jaffray on their part issued Overweight rating on November 25, 2019.

Most Popular

Related Posts